Lyell Immunopharma Inc (LYEL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.37+0.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LYEL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress the PiNACLE and PiNACLE-H2H pivotal trials for ronde-cel in relapsed/refractory large B-cell lymphoma, aiming for pivotal data mid-2027 and BLA submission in second half of 2027.
Stated as a priority in 3 of last 3 quarters. Management consistently emphasized advancing the PiNACLE and PiNACLE-H2H pivotal trials for ronde-cel with pivotal data expected mid-2027 and BLA submission thereafter. No revenue impact yet; clinical progress is ongoing and trajectory matches stated plans.
“PiNACLE pivotal trial ongoing; pivotal data expected mid-2027; BLA submission expected second half 2027.”
“PiNACLE pivotal trial ongoing; pivotal data expected mid-2027; BLA submission expected in 2027.”
“PiNACLE pivotal trial ongoing; pivotal data expected mid-2027; BLA submission expected second half 2027.”
Continue Phase 1/2 clinical trial of LYL273 with safety improvements and dose escalation, aiming for additional data and FDA End-of-Phase 1 meeting in second half of 2026.
Stated as a priority in 3 of last 3 quarters. Management has focused on advancing LYL273 clinical trials with improved safety protocols reducing Grade ≥2 diarrhea or colitis from 55% to 10%, and trial design amended to Phase 1/2. Clinical data updates and FDA meetings are expected in second half 2026, indicating delivering progress.
“Updated safety data for LYL273 showed reduced Grade ≥2 diarrhea or colitis from 55% to 10% with GI prophylaxis; Phase 1 trial amended to Phase 1/2 design.”
“Phase 1 clinical trial of LYL273 continues enrolling patients; dosing commenced at Dose Level 3.”
“LYL273 acquired with promising dose-dependent clinical activity; FDA granted Fast Track designation.”
Manage cash, cash equivalents, and marketable securities to ensure sufficient runway for working capital and capital expenditures through Q3 2027.
Stated as a priority in 4 of last 4 quarters. Cash, cash equivalents and marketable securities declined from $261.0 million in 2026-Q1 to $228.0 million in 2026-Q2 but management maintains that current balances are sufficient to meet working capital and capital expenditure needs into Q3 2027. The trajectory is consistent with stated cash sufficiency goals.
“Cash, cash equivalents and marketable securities expected to provide runway into Q3 2027.”
“Cash, cash equivalents and marketable securities balances sufficient to meet working capital and capital expenditure needs into Q3 2027.”
“Cash, cash equivalents and marketable securities balances sufficient to meet working capital and capital expenditure needs into Q3 2027.”
“Cash, after $40 million payment for LYL273 license, expected to meet working capital and capital expenditure needs into 2027.”
Manage R&D and G&A expenses with focus on clinical trial activity and personnel costs to optimize operating expenses.
Stated as a priority in 3 of last 3 quarters. R&D expenses increased from $36.6 million in 2026-Q1 to $39.5 million in 2026-Q2 due to clinical trial activity, partially offset by personnel cost reductions. G&A expenses remained stable at $9.6 million. Management is balancing expense control with clinical progress, showing mixed but consistent focus.
“R&D expenses increased $4.7 million due to clinical trial activity, partially offset by $4.2 million decrease in facilities and personnel expenses; G&A expenses decreased slightly.”
“R&D expenses decreased $6.8 million due to personnel expense reduction, partially offset by increased clinical trial activity; G&A expenses decreased $4.5 million due to personnel-related expenses.”
“R&D and G&A expenses discussed with focus on managing clinical trial and personnel costs.”
Lower net cash use in 2025 to between $155M and $160M, excluding a $40M upfront payment.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 0.93x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
19 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.